Adjuvant atezolizumab benefits PD-L1-selected patients with NSCLC
Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio CHICAGO — Updated survival data from the randomized phase 3 …